XNASRENB
Market cap112mUSD
Jan 17, Last price
0.71USD
1D
-5.73%
1Q
3.97%
IPO
-5.98%
Name
Enochian Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.71%
Rev. gr., 5y
%
Revenues
0k
Net income
-81m
L+103.23%
CFO
-11m
L-6.82%
Earnings
Feb 12, 2025
Profile
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 27,388 | 19,597 | 22,826 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (27,388) | (19,597) | (22,826) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 707 | 34 | |||||||
Tax Rate | |||||||||
NOPAT | (27,388) | (20,304) | (22,826) | ||||||
Net income | (80,650) 103.23% | (39,684) -65.02% | (113,433) 324.47% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,000 | 4,012 | 4,676 | ||||||
BB yield | -1.78% | ||||||||
| Debt | |||||||||
Debt current | 2,945 | 4,818 | 1,454 | ||||||
Long-term debt | 2,178 | 1,745 | 6,802 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 4,902 | 4,688 | (916) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (10,971) | (11,775) | (15,732) | ||||||
CAPEX | (70) | (30) | (5) | ||||||
Cash from investing activities | (1,260) | (30) | (5) | ||||||
Cash from financing activities | 10,517 | 4,515 | 4,250 | ||||||
FCF | (5,757) | (16,344) | (22,415) | ||||||
| Balance | |||||||||
Cash | 220 | 1,874 | 9,172 | ||||||
Long term investments | |||||||||
Excess cash | 220 | 1,874 | 9,172 | ||||||
Stockholders' equity | (324,835) | (244,053) | (204,370) | ||||||
Invested Capital | 460,367 | 296,149 | 284,006 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 96,248 | 56,265 | 52,528 | ||||||
Price | 1.75 | ||||||||
Market cap | 168,434 | ||||||||
EV | 173,337 | ||||||||
EBITDA | (27,266) | (19,483) | (22,703) | ||||||
EV/EBITDA | |||||||||
Interest | 1,011 | 707 | 373 | ||||||
Interest/NOPBT | |||||||||